Needham analyst Michael Matson maintained a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $5.00. The company’s shares closed last Tuesday at $2.19, close to its 52-week low of $1.80.
According to TipRanks.com, Matson is a 4-star analyst with an average return of 8.7% and a 53.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 105.6% upside from current levels. In a report issued on January 5, Piper Sandler also initiated coverage with a Buy rating on the stock with a $3.10 price target.
OncoCyte’s market cap is currently $202M and has a P/E ratio of -5.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
Read More on OCX:
- DR Horton (DHI) was Downgraded to a Hold Rating at KeyBanc
- KB Home (KBH) Got Some Bad News
- Analysts Offer Insights on Consumer Goods Companies: Trigano SA (OtherTGNOF) and Lennar (LEN)
- Meta Platforms: Could Growth Accelerate in 2022?
- H.C. Wainwright Thinks ADC Therapeutics’ Stock is Going to Recover